Drug Profile


Alternative Names: R-1678; RG 6718; RG-6178; RG1678; RO-4917838

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Roche
  • Developer Chugai Pharmaceutical; Roche
  • Class Antipsychotics; Piperazines; Pyridines; Small molecules
  • Mechanism of Action Glycine transporter 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Obsessive-compulsive disorders; Schizophrenia

Most Recent Events

  • 07 Sep 2017 Roche plans a phase II trial for Beta-thalassaemia in Lebanon(NCT03271541)
  • 01 Dec 2014 Roche completes a phase III trial in Schizophrenia in USA, Bulgaria, China, Czech Republic, Italy, Russia and Japan (NCT01235559; EudraCT2010-020718-26; WN25305)
  • 16 Oct 2014 Discontinued - Phase-III for Schizophrenia in USA, Turkey, Netherlands, Chile, Ukraine, Taiwan, Spain, Poland, Lithuania, Slovakia, Latvia, Germany, Canada, Brazil, Finland, India, Hungary, France, Columbia, Argentina, South Korea, Mexico, Romania, Russia, United Kingdom, Italy, Sweden, Czech Republic, Australia, China, Bulgaria, Japan (PO) (Roche pipeline)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top